康复新液辅助治疗颈淋巴结核的临床效果.docVIP

康复新液辅助治疗颈淋巴结核的临床效果 　　[摘要] 目的 观察康复新液对颈淋巴结核的辅助治疗效果。 方法 将2012年6月～2013年6月江苏省无锡市第五人民医院收治的100例颈淋巴结核患者按随机数字表法分为对照组和治疗组，每组50例。对照组常规应用利福平、异烟肼、吡嗪酰胺、乙胺丁醇进行抗结核治疗，治疗组在对照组的基础上加用康复新液。比较不同时间两组患者的症状缓解率、淋巴结吸收率、术后复发率和不良反应及并发症情况。 结果 治疗组1个月、3个月和6个月临床症状缓解率为90%、98%和100%，较对照组的58%、68%和86%显著升高，差异有高度统计学意义（P 0.01）。治疗组1个月、3个月和6个月的淋巴结吸收率分别为64%、86%和94%，高于对照组的32%、60%和84%，差异有统计学意义（P 0.05）。与对照组比较，治疗组患者术后复发率和不良反应及并发症的发生率均降低，差异有统计学意义（P 0.05）。 结论 康复新液联合常规抗结核药可提高颈部淋巴结核的症状缓解率和淋巴结吸收率，降低复发率和不良反应及并发症的发生率，值得临床推广使用。 　　[关键词] 康复新液；辅助治疗；颈淋巴结核；临床效果 　　[中图分类号] R522 [文献标识码] A [文章编号] 1673-7210（2014）09（a）-0078-04 　　[Abstract] Objective To observe clinical effect of Kangfuxin Solution （KFXS） adjuvant treating cervical tuberculosis lymphadenitis （CTL）. Methods 100 CTL patients who were treated in the 5th Peoples Hospital of Wuxi City from June 2012 to June 2013 were divided into control group and treatment group by digital random method， with 50 cases in each group. Control group was treated with routine application of anti-tuberculosis treatment with Rifampin， Isoniazid， Pyrazinamide and Ethambutol. Treatment group used KFXS on the basis of the control group. Lymph nodes symptom remission rate， absorption rate， postoperative recurrence rate and adverse reactions and complications incidence were compared. Results Clinical symptom relief rate in treatment group after treated for 1 month， 3 months and 6 months were 90%， 98% and 100% respectively， which were significantly higher than 58%， 68% and 86% in the control group. The differences were statistically significant （P 0.01）. Lymph node absorption rate in treatment group after treated for 1 month， 3 months and 6 months were 64%， 86% and 94% respectively， which were higher than 32%， 60% and 84% in control group， the differences were statistically significant （P 0.05）. Compared with control group， postoperative recurrence rate and the incidence of adverse reactions and complications in treatment group were reduced， the differences were statistically significan